- Goldman Sachs reaffirmed its ‘Buy’ rating for NVIDIA, setting a $250 price target that suggests a 51% upside from recent levels.
- The firm’s analysts identified healthcare and life sciences as key growth drivers, with strategic biotech partnerships allowing Nvidia to refine its AI models in real-world labs.
- Nvidia’s collaboration with Recursion Pharmaceuticals demonstrates tangible AI efficiencies, accelerating drug discovery timelines.
- Despite the positive analyst outlook, retail investor sentiment on platforms like Stocktwits remained bearish as of March 31, 2026.
On March 31, 2026, Goldman Sachs maintained its bullish stance on Nvidia Corp., according to a CNBC report. The firm reiterated a ‘Buy’ rating with a $250 price target, signaling strong conviction in the chipmaker’s future amid rising AI demand. This target implied a potential 51% gain from the stock’s closing price earlier that week.
Analyst Salveen Richter highlighted Nvidia’s deepening collaborations with biotech firms as a major catalyst. These partnerships enable the testing and validation of AI models in laboratory environments, expanding applications into digital health and manufacturing. Consequently, the expanding use cases in drug development and clinical research may unlock meaningful upside for the semiconductor leader.
The strategic investment in Recursion Pharmaceuticals Inc. is already yielding results. Recursion reported that its AI-powered platform drastically reduces the number of compounds needing synthesis and shortens timelines to human testing. Meanwhile, machine learning is also improving clinical trial design by enhancing patient group identification and data analysis.
Nvidia’s stock traded over 3% higher following the analyst note. However, retail sentiment on Stocktwits remained in ‘bearish’ territory with low message volume. This contrasted with the professional analyst optimism, as Nvidia’s shares had declined over 8% year-to-date by that point.
✅ Follow BITNEWSBOT on Telegram, Facebook, LinkedIn, X.com, and Google News for instant updates.
Previous Articles:
- Memescope Monday Memecoin Event Misses Mark, Leaves Traders Bleeding
- OpenFX Raises $94M Series A for Stablecoin Payments Growth
- Dromos Launches Predictive Allocation for Real-Time Voting
- Senators Probe SEC Over Favoritism in Trump-Linked Crypto Cases
- Sen. Blumenthal Probes SEC for Crypto Favoritism to Trump Allies
